Figure 6. Neuroblastoma arginase activity impair T cell immunotherapies and haematopoietic stem cell division.

a) T cells from neuroblastoma patients at diagnosis had decreased proliferative potential compared to those from healthy donors. b) Neuroblastoma conditioning suppresses NY-ESO-1 TCR engineered T cell proliferation. Data representative of 3 independent experiments c) Neuroblastoma conditioning suppresses anti-GD2 CAR T cell cytotoxicity against neuroblastoma. Data representative of 2 independent experiments d). Arginase inhibition during neuroblastoma conditioning rescues anti-GD2 CAR T cell cytotoxicity. Data representative of 2 independent experiments e) Neuroblastoma patient plasma suppresses human CD34⁺ HSC proliferation. Data are representative of five patient plasma experiments. Independent experiments were performed on two separate occasions. f) CD34+ HSC proliferation is inhibited by the neuroblastoma low-arginine microenvironment. Independent experiments were performed on two separate occasions.